Xbrane Biopharma

Xbrane Biopharma AB is a biotechnology company specializing in the development of biosimilars, which are follow-up drugs introduced at a lower price after the original drug's patent expires. Utilizing a patented platform technology, Xbrane reduces production costs of biological drugs, making them more accessible globally. The company is committed to promoting health equality by providing cost-effective treatments for serious medical conditions. Headquartered in Solna, Sweden, Xbrane is listed on Nasdaq Stockholm and collaborates with global pharmaceutical companies to enhance market reach and product launches.

7.12

2.43

— Xbrane Biopharma
%
Biosimilars70% Includes follow-up drugs for existing biologics at lower costs
Platform Technology15% Proprietary technology for cost-effective drug production
Strategic Partnerships15% Collaborations to enhance drug development and market reach

Xbrane Biopharma's customers include large pharmaceutical companies and healthcare providers seeking cost-effective...

  • Pharmaceutical Companiesprimary

    Purchase biosimilars for distribution and market expansion

  • Healthcare Providerssecondary

    Utilize cost-effective biosimilars for patient treatments

  • Strategic Partnersemerging

    Collaborate on drug development and market penetration

Xbrane Biopharma is headquartered in Solna, Sweden, with a significant presence in Europe, where it has launched its...

  • •Headquartered in Solna, Sweden
  • •Products launched in 24 European countries
  • •Expanding presence in North America and Asia
  • •Global partnerships to penetrate new markets
  • •Focus on health equality through worldwide accessibility

Xbrane Biopharma's strategic priorities include expanding its biosimilar portfolio and enhancing market penetration...

01
Expand biosimilar portfoliomedium-term

To address more treatment areas and increase market share

02
Enhance market penetrationshort-term

To maximize reach and sales through strategic collaborations

03
Leverage proprietary technologylong-term

To maintain competitive advantage and reduce costs

Xbrane Biopharma faces several risks, including regulatory challenges related to biosimilar approvals, particularly in...

critical

Regulatory challenges

FDA approval process for biosimilars is stringent

Materiality
high
high

Partnership reliance

Dependence on partners for market penetration

Materiality
medium
high

Financial sustainability

Need for long-term financing solutions

Materiality
high
Revenue recognition timing
high
Estimates and provisions
medium
Seasonality in revenue
medium

SUTRO BIOPHARMA, INC.

STRO · Biological Products, (No Diagnostic Substances)

XBiotech Inc.

XBIT · Pharmaceutical Preparations

Xencor Inc

XNCR · Pharmaceutical Preparations

BioArctic

BIOA-B.ST · Health Care

EXICURE, INC.

XCUR · Pharmaceutical Preparations

Zenas BioPharma, Inc.

ZBIO · Pharmaceutical Preparations

: 11/08/2026